This press release is worth a read for a number of reasons
- Hemp products being used increasingly for medical research
- The Chinese are getting into the hemp market in a big way
- And hemp and IP issues
NEW YORK, October 2, 2017 /PRNewswire/ —
The report indicates that the total retail value of hemp products sold in the U.S. in 2016 was $688 million. As a result of successful legalization campaigns across several U.S. states and successful hemp cultivation pilot programs, sales of items like shelled seed, protein powder, soaps and lotions have continued to increase. In all, sales of Hemp CBD products boosted the industry to a five year 22% CAGR. Chineseinvestors.com, Inc. (OTC: CIIX), Medical Marijuana, Inc. (OTC: MJNA), Cannabis Sativa, Inc. (OTC: CBDS), CV Sciences, Inc. (OTC: CVSI), Terra Tech Corp. (OTC: TRTC)
A report by New Frontier Data points out the role of cannabis products for medical use in the pharmaceutical market. “The United States constitutes 35% of the global pharmaceutical market, the largest market in the world, and a major driver of the U.S. economy. It is one of many industries that will be impacted by the growth of the legal cannabis market and we are already starting to see that trend in legal medical states where use of key prescription drugs is down by 11%. If cannabis were to be adopted nationally, we would begin to see a trend of patients turning to medical cannabis as a substitute or complement to pharmaceuticals,” said Giadha Aguirre De Carcer, CEO & Founder of New Frontier Data.
Chineseinvestors.com, Inc. (OTCQB: CIIX) just announced breaking news this morning that it has appointed Skin Care Industry veteran and Shanghai beauty influencer, Fannie (Chun Fang) Tang Marketing Director of its wholly owned foreign enterprise, CBD Biotechnology Co., Ltd. effective immediately. Ms. Tang will report directly to CBD Biotechnology’s CEO, Summer Yun, and will be responsible for developing and implementing branding strategies for CBD Biotechnology’s CBD Magic Hemp Series skin care line in China. With over 20 years’ experience in the industry, Tang was highlighted in the book entitled Shanghai Beauty 26 as a leading influencer in Shanghai’s beauty culture. Ms. Tang served as the CEO of L. D. Waxson Group’s China Division until it was acquired in 2012 by India’s third largest software services provider, Wipro Limited, for $144 million. L.D. Waxson, a leading skin care company with manufacturing facilities in China and Malaysia, and a strong footprint in Singapore, Malaysia, China, Taiwan, Hong Kong and Thailand, reported revenues of approximately $68m prior to its acquisition in 2012. It’s portfolio of brands included the skin care lines Bioessence and Ginvera, and Ebene, a popular health care brand.
“With over twenty years’ of marketing and branding experience in the skin care and cosmetics industry, I believe CBD Biotechnology is extremely fortunate to be working with Ms. Tang,” says Yun. “Ms. Tang’s concept of “Beauty Derives from Nature and Creation” aligns with CBD Biotechnology’s vision to develop an innovative, natural skin care band. Moreover, Ms. Tang has proven success in the industry in this region. Through her efforts, we are confident that CBD Biotechnology will position itself to become a leader in China’s skin care industry.”
In September 2017, CBD Biotechnology completed the filing process with the China Food & Drug Administration for its first three products in the CBD Magic Hemp Series line, namely the CBDBIO TECH Brightening and Refreshing Moisturizer, the CBDBIO TECH Perfecting Shield Primer, and the CBDBIO TECH Peptide Collagen Solution, which are expected to be formally launched this month. The CBD Magic Hemp Series skin care line will be marketed through multiple sales channels, including online sales, app sales, and third party distribution relationships with online celebrities and market influencers.
“China can to be a complex business culture to navigate,” says ChineseInvestors.com, Inc.’s CEO Warren Wang. As such, a company’s management and leadership team is critical to its success. Ms. Tang is a proven marketing leader and beauty influencer in China. With Ms. Tang’s expertise and a breakthrough hemp-infused skin care line, I believe we have the key elements for success in this market.”
“I am honored to serve as the Marketing Director of CBD Biotechnology,” says Tang. “Hemp extract, otherwise known as cannabidiol or CBD, is a powerful antioxidant and anti-inflammatory agent making it a perfect ingredient for skin care products. CBD Biotechnology will be among the first skin care companies in China to infuse its products with natural hemp extract making it a pioneer in this segment of the skin care industry. I believe CBD Biotechnology has a unique opportunity to take the lead in the Chinese market with its innovative skin care line.”
Medical Marijuana, Inc. (OTC: MJNA) strives to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. On September 22nd, Medical Marijuana, Inc., portfolio company, Kannalife Sciences, Inc., a pharmaceutical and phyto-medical company, announced that former three time NFL Pro-Bowl and Kansas City Chiefs placekicker, Nick Lowery, has joined Kannalife corporate advisory board to lead the Company’s initiative on speaking about chronic traumatic encephalopathy (CTE) and Kannalife’s efforts to bring forth a clinically approved treatment for CTE. Kannalife Sciences holds the exclusive license from the federal government to commercialize a cannabinoid patent currently held by the U.S. Government and National Institutes of Health (NIH).
Cannabis Sativa, Inc. (OTCQB: CBDS) is engaged in the licensing of cannabis related intellectual property, marketing and branding for cannabis based products and services, operation of cannabis related technology services, and ancillary business activities. On August 2nd, Cannabis Sativa, Inc. announced that the Company has acquired a controlling interest in PrestoCorp (a.k.a. PrestoDoctor), an online telemedicine platform providing access to knowledgeable physicians for a safe and confidential way to get a medical marijuana recommendation using secure video conferencing technology.
CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. Earlier in July, CV Sciences, Inc., provided an update on published outcomes of recent clinical research on pharmaceutical-grade cannabidiol (CBD) pointing to its therapeutic potential as a prescription drug. In The New England Journal of Medicine published on May 25, 2017, a clinical trial of pharmaceutical-grade CBD as an adjunct to standard anticonvulsive therapy sponsored by GW Pharmaceuticals in the control of a rare unremitting, drug-resistant seizure disorder, Dravet’s syndrome, demonstrated a statistically significant reduction in the number of seizures in the patients receiving CBD versus placebo while both groups were maintained on standard anticonvulsants.
Terra Tech Corp. (OTCQX: TRTC), a vertically integrated cannabis-focused agriculture company, on September 19th, announced that it has signed its second Craft Cultivator to grow the Company’s proprietary high grade “IVXX” cannabis flowers and oils. The farm, Cultivar Inc., is located in Salinas, California and is approved for up to six acres (approximately 244,000 square feet) of cannabis cultivation, to be grown in high tech, climate-controlled greenhouses.